肺动脉高压中激活素信号系统的血清与肺组织表达谱
研究在80例新诊断特发性、遗传性或食欲抑制剂相关肺动脉高压患者中检测血清激活素A、激活素B、抑制素α亚基及拮抗剂卵泡抑素和FSTL3,主要终点为死亡或肺移植。中位随访69个月,26例(32.5%)发生终点事件,基线和随访时激活素A与FSTL3均与无移植生存相关,阈值分别为393 pg/mL和16.6 ng/mL,并在外部验证队列中证实。
要点
- 激活素A和FSTL3是肺动脉高压无移植生存的预后生物标志物
- 基线激活素A<393 pg/mL和FSTL3<16.6 ng/mL与更好生存相关
- 肺组织中激活素受体和FSTL3表达上调,抑制素α和卵泡抑素下调
核心结论
- 激活素A和FSTL3是肺动脉高压的预后生物标志物。
研究设计与样本
- 在80例新诊断特发性、遗传性或食欲抑制剂相关肺动脉高压患者和对照中测量血清激活素A、激活素B、抑制素α亚基、卵泡抑素和FSTL3,基线和治疗开始后3至4个月各测一次。
- 分析肺动脉高压和对照肺组织中抑制素亚基、卵泡抑素、FSTL3、Bambi、Cripto及激活素受体ALK和ACTRII、betaglycan的表达模式。
主要发现
- 中位随访69个月(四分位距50-81个月),80例中26例(32.5%)发生死亡或肺移植。
- 年龄和性别调整模型中,基线激活素A(HR 1.001,95%CI 1.000-1.001,P=0.037)和FSTL3(HR 1.263,95%CI 1.049-1.520,P=0.014)与无移植生存相关。
- 随访时激活素A(HR 1.003,95%CI 1.001-1.005,P=0.001)和FSTL3(HR 1.365,95%CI 1.185-1.573,P<0.001)与无移植生存相关。
- ROC分析确定阈值:激活素A 393 pg/mL,FSTL3 16.6 ng/mL。
- 进一步调整NYHA功能分级、6分钟步行距离和NT-proBNP后,基线激活素A<393 pg/mL的HR为0.14(95%CI 0.03-0.61,P=0.009),FSTL3<16.6 ng/mL的HR为0.17(95%CI 0.06-0.45,P<0.001);随访时对应HR分别为0.23(95%CI 0.07-0.78,P=0.019)和0.27(95%CI 0.09-0.78,P=0.015)。
关键数值与推荐
- 激活素A阈值393 pg/mL,FSTL3阈值16.6 ng/mL,由ROC分析确定。
临床怎么用
- 激活素A和FSTL3可作为肺动脉高压预后评估的血清生物标志物,基线及随访水平均与无移植生存相关。
局限性
- 研究样本量80例,为单中心队列,需外部验证确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Activins are novel therapeutic targets in pulmonary arterial hypertension (PAH). We therefore studied whether key members of the activin pathway could be used as PAH biomarkers. METHODS: Serum levels of activin A, activin B, α-subunit of inhibin A and B proteins, and the antagonists follistatin and follistatin-like 3 (FSTL3) were measured in controls and in patients with newly diagnosed idiopathic, heritable, or anorexigen-associated PAH (n=80) at baseline and 3 to 4 months after treatment initiation. The primary outcome was death or lung transplantation. Expression patterns of the inhibin subunits, follistatin, FSTL3, Bambi, Cripto, and the activin receptors type I (ALK), type II (ACTRII), and betaglycan were analyzed in PAH and control lung tissues. RESULTS: Death or lung transplantation occurred in 26 of 80 patients (32.5%) over a median follow-up of 69 (interquartile range, 50-81) months. Both baseline (hazard ratio, 1.001 [95% CI, 1.000-1.001]; P=0.037 and 1.263 [95% CI, 1.049-1.520]; P=0.014, respectively) and follow-up (hazard ratio, 1.003 [95% CI, 1.001-1.005]; P=0.001 and 1.365 [95% CI, 1.185-1.573]; P<0.001, respectively) serum levels of activin A and FSTL3 were associated with transplant-free survival in a model adjusted for age and sex. Thresholds determined by receiver operating characteristic analyses were 393 pg/mL for activin A and 16.6 ng/mL for FSTL3. When adjusted with New York Heart Association functional class, 6-minute walk distance, and N-terminal pro-B-type natriuretic peptide, the hazard ratios for transplant-free survival for baseline activin A <393 pg/mL and FSTL3 <16.6 ng/mL were, respectively, 0.14 (95% CI, 0.03-0.61; P=0.009) and 0.17 (95% CI, 0.06-0.45; P<0.001), and for follow-up measures, 0.23 (95% CI, 0.07-0.78; P=0.019) and 0.27 (95% CI, 0.09-0.78, P=0.015), respectively. Prognostic values of activin A and FSTL3 were confirmed in an independent external validation cohort. Histological analyses showed a nuclear accumulation of the phosphorylated form of Smad2/3, higher immunoreactivities for ACTRIIB, ALK2, ALK4, ALK5, ALK7, Cripto, and FSTL3 in vascular endothelial and smooth muscle layers, and lower immunostaining for inhibin-α and follistatin. CONCLUSIONS: These findings offer new insights into the activin signaling system in PAH and show that activin A and FSTL3 are prognostic biomarkers for PAH.
引用
- Guignabert C, Savale L, Boucly A, et al. Serum and Pulmonary Expression Profiles of the Activin Signaling System in Pulmonary Arterial Hypertension. Circulation. 2023. PMID: 37096577. doi:10.1161/CIRCULATIONAHA.122.061501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。